Therefore, enhanced tumor immunogenicity, activated antitumor immunity, and elevated PD-1, PD-L1, and CTLA4 expression could explain why NOTCH4-MUT tumors are more likely than NOTCH4-WT tumors to benefit from immunotherapy. This evidence concerns the gene NOTCH4 and neoplasm.